Renovion

Focus: Renovion is a public-stage biotechnology company focused on nebulized mucus clearance therapy for rare respiratory diseases, headquartered in Chapel Hill, NC. The company operates a focused pipeline targeting unmet needs in bronchiectasis and bronchiolitis obliterans syndrome.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Renovion

AI assessmentNot Hiring

No open roles listed right now. Follow Renovion to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ARINA-1

Tracheostomy

PHASE_1

Clinical Trials (1)

NCT05658029An Investigator-initiated Study to Evaluate Safety and Efficacy of ARINA-1 in People With a Tracheostomy

Phase 1

Help build intelligence for Renovion

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Leading rare disease respiratory focus with ARINA-1 in Phase 3 for Pre-Bronchiolitis Obliterans Syndrome, representing a near-term clinical catalyst
Multi-indication pipeline depth with same asset in Phase 2 (Non-CF Bronchiectasis) and Phase 1 (Tracheostomy), offering career progression through multiple clinical programs
Public company status provides equity upside potential and access to capital markets for biotech professionals seeking growth-stage exposure

Watch Out For

Currently zero active job openings despite public status suggests limited near-term hiring and potential restructuring focus
Extremely limited public visibility with only 1 published paper and no recent news coverage, indicating early-stage market awareness and execution risk

Generated by Claude from Renovion's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ARINA-1

Non-cystic Fibrosis Bronchiectasis

PHASE_2

Clinical Trials (1)

NCT05495243Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

Phase 2

ARINA-1

Pre-Bronchiolitis Obliterans Syndrome

PHASE_3

Clinical Trials (1)

NCT05654922Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

Phase 3